Exchange: OTC·Updated 03:58 PM EST

BCLI News

News
all
press releases
The company plans to move its shares to the OTCQB market and says the delisting won't impact its ALS research or upcoming Phase 3b trial.
Stocktwits
BrainStorm Cell Therapeutics plans to enroll 200 ALS patients in its FDA-cleared Phase 3b trial of NurOwn, with a 24-week double-blind phase followed by an open-label extension.
Stocktwits
Your Only Digest of Market-Moving News and Rumours From High-Growth, Small Cap Stocks
Stocktwits Contributor

Advertisement|Remove ads.